European Panel OKs Amgen Cancer Drug

0

Amgen Inc. said Friday that it won a European regulatory panel recommendation for clearance of its cancer drug Vectibix — provided the thousand Oaks-based biotech provides the panel with additional information on safety and effectiveness.


This is the European Committee for Medicinal Products’ second ruling on the drug. In May the panel did not approve use of the drug citing insufficient evidence of effectiveness. The drug is recommended to be used in colorectal cancer patients whose tumors contain a particular type of gene, the agency said.


In the review, the panel concluded that the benefits of using the drug outweighed the risks. The drug was approved for use in the U.S. about a year ago. Sales in the first two quarters of 2007 have totaled $96 million, according to Amgen.

No posts to display